Evidence map›Paper›PMID 32611965›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia.

Hiroyasu Inoue, Hirofumi Taji, Kentaro Yamada, Chisako Iriyama, Touko Saito, Harumi Kato, Masamitsu Yanada, Kazuhito Yamamoto, Noriyuki Matsukawa

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hiroyasu InoueDepartment of Neurology, Nagoya City East Medical Center, Japan.
Hirofumi TajiDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan.
Kentaro YamadaDepartment of Neurology, Nagoya City East Medical Center, Japan.
Chisako IriyamaDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan.
Touko SaitoDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan.
Harumi KatoDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan.
Masamitsu YanadaDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan.
Kazuhito YamamotoDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan.
Noriyuki MatsukawaDepartment of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Sciences, Japan.
Aichi Cancer Center · JPNagoya Medical Center · JPFujita Health University · JPNagoya City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dasatinib, a tyrosine kinase inhibitor, is commonly used in the treatment of chronic myelogenous leukemia. A rare side effect is peripheral neuropathy. A 54-year-old woman experienced gradually accelerated dysesthesia and hypoesthesia in her extremities, 2 months following treatment with dasatinib. Nerve conduction studies revealed a prolonged conduction velocity with temporal dispersion, indicating demyelinating peripheral neuropathy. After changing dasatinib to nilotinib, both her clinical symptoms and electrophysiological data gradually improved. We herein report the findings of this case with a review of the pertinent literature.

Indexed as

Antineoplastic AgentsDasatinibFemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiddle AgedPeripheral Nervous System DiseasesProtein Kinase InhibitorsPyrimidinesTreatment OutcomeAntineoplastic AgentsDasatinibProtein Kinase InhibitorsPyrimidineschronic myelogenous leukemiadasatinibdemyelinating peripheral neuropathynilotinibtyrosine kinase inhibitor

Identifiers

PMID32611965
PMCPMC7644482
OpenAlexW3039904645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.